Google has failed in its bid to stay a competition lawsuit brought by Epic Games, after failing to show that the Fortnite game maker would not be disadvantaged if the case were heard in California instead.
Google has urged a court to stay a competition lawsuit brought by Epic Games, saying new evidence showed the Fortnite game maker would not be disadvantaged if the case was heard in California, as the Full Court found it would in a similar challenge by Apple.
A judge has issued a stern warning to litigation funders seeking to take a āgambleā on pending court proceedings, ruling they could be held liable for costs if their intervention proves critical to the advancement of the case.
Gina Rinehart’s Hancock Prospecting has failed to persuade a court to hold an expanded separate trial on the alleged wrongdoing of the mining magnate in a spat over the Hope Downs iron ore mine, with a judge finding the proposal could extend the already ten-year legal battle.
Shareholders of the collapsed Babcock & Brown have failed in their challenge to a ruling tossing their cases for damages for disclosure breaches during the global financial crisis, with an appeals court finding the investors had not shown the breaches caused any loss.
An appeals court has upheld a ruling that Sydney law firm Atanaskovic Hartnell was not entitled to the bulk of $165,000 in legal fees charged to two media company clients defrauded by jailed former solicitor Brody Clarke, calling the firm’s attempt to renege on its undertakings “dishonourable”.
Apple plans to appeal the Full Federal Court’s decision that Epic Games’ misuse of market power lawsuit over it App Store terms should be heard in Australia because the case raises issues of “fundamental public interest”.
Video game developer Epic Games has asked the Full Federal Court to overturn an “illogical” decision sending its competition lawsuit against Apple to California, saying the move would have a “chilling effect” on the enforcement of Australia’s competition laws.
A judge has given Generic Health more time to file its evidence in a multimillion-dollar dispute with drug makers Otsuka and Bristol-Myers Squibbs over the delayed launch of generic versions of their antipsychotic drug Abilify, but warned there had to be a cut-off point for preparing the decade-long dispute for trial.
The companies behind the top selling Abilify medication have lost their latest bid for documents from the Commonwealth in a multimillion dollar dispute over the delayed listing of generic versions of their drug, with a judge saying the material could be only “of the most marginal relevance”.